Hormones After Cancer and in Midlife: Clearing the Myths, Restoring Quality of Life
A recent conversation on the You Are Not Broken podcast captured something rare in women’s health: two clinicians who refuse to oversimplify hormones, who distinguish molecule from molecule, and who put quality of life back at the center for women—especially those living with or after cancer.
Who Is Speaking
The episode features Dr. Linda Bosserman, MD, PhD, a board-certified medical oncologist and full professor at City of Hope National Cancer Center. After decades as a breast medical oncologist and value-based care specialist, she earned a PhD in sex therapy during the pandemic. She now runs a focused clinic (currently booked months out) for women experiencing sexual, menopausal, or andropausal side effects after cancer treatment. She lectures, publishes, and co-authors editorials aimed at correcting persistent misconceptions.
Her conversation partner is the host of You Are Not Broken, a urologist and sexual-medicine clinician who met Bosserman at a conference when Bosserman publicly corrected presenters on the critical differences between progesterone and synthetic progestins, and between conjugated equine estrogens and estradiol. The two have already co-authored editorials and share a practical, data-driven stance: the “bio” in biopsychosocial matters, and women deserve accurate information rather than fear-based blanket prohibitions.
Actionable Insights from the Conversation
Hormone type, dose, and route are not interchangeable. Saying “hormones” without specifying is clinically useless and often harmful.
Estradiol does not equal conjugated equine estrogens. Natural progesterone does not equal synthetic progestins. Testosterone is not merely a “libido drug.”
Local (vaginal) low-dose estradiol is supported by large observational data even after breast cancer and should be considered standard for genitourinary symptoms.
Systemic hormones after breast, endometrial, or ovarian cancer require individualized discussion of recurrence risk, symptoms, and priorities—not automatic refusal.
Testosterone offers benefits well beyond sexual desire: energy, cognition, mood, and the subjective return of “color” to life.
Media and some journal articles continue to overgeneralize weak or confounded data; clinicians and patients must demand specificity.
Quality of life, cardiovascular risk, bone health, sleep, and metabolic health are legitimate treatment goals alongside cancer surveillance.
What the Data Actually Suggests About Cancer Risk
Factors with clearer associations to increased breast-cancer risk (or poorer outcomes):
Synthetic high-dose progestins (the combination arm of the Women’s Health Initiative and certain other studies showed a small absolute increase, on the order of 1 in 1,000 or comparable to daily alcohol or obesity).
Obesity, chronic inflammation, sedentary lifestyle, and poor metabolic health.
Alcohol consumption.
What current evidence does not support as major drivers of increased risk when used appropriately:
Estradiol (bioidentical 17β-estradiol), whether oral or transdermal, does not show the breast-cancer signal once attributed to all “hormones.” Long-term data, including the Danish Osteoporosis Prevention Study (DOPS) and other trials, show no increase and, in some cases, cardiovascular and mortality benefits.
Testosterone. Observational series (including large pellet data compared with SEER baselines and other cohorts) have shown lower-than-expected breast-cancer rates—sometimes 30–50% reductions in reported analyses. Conversion to estrogen is limited, especially on aromatase inhibitors.
Natural (micronized) progesterone used in physiologic regimens.
Low-dose vaginal estradiol after breast cancer (tens of thousands of women studied; systematic reviews and meta-analyses support safety, including with aromatase inhibitors).
Conjugated equine estrogens (Premarin) used alone (estrogen-only arm of WHI and longer follow-up) actually showed a reduction in breast-cancer incidence in the original data.
The 2002 Women’s Health Initiative media coverage created an “Iron Curtain” that still leads many clinicians and patients to ignore pre-2002 data and to treat all menopausal hormone therapy as equivalent. Studies that lump unknown doses, routes, and types of “hormones” into one category and then report dramatic relative risks should be viewed with extreme caution.
Benefits of Testosterone in Women
Bosserman and the host emphasize that framing testosterone solely as a treatment for low libido is both incomplete and counterproductive. Women report:
Restoration of energy, mental clarity, and the feeling that “the world is in color again” or that the brain has shifted from black-and-white to Technicolor.
Improved motivation, reduced anxiety/depression symptoms in some, and better response to the physical and cognitive demands of daily life.
Local tissue effects (clitoral and labial tissue responsiveness) that contribute to sexual function and comfort.
Support for overall well-being that makes other healthy behaviors (exercise, sleep, intimacy) more achievable.
Typical physiologic dosing is individualized (commonly starting in the low milligram range and titrated to symptom response and levels). Women generally self-regulate; they do not seek “off-the-ceiling” libido. The absence of an FDA-approved female-dose product remains a major access and equity issue, especially compared with the current FDA interest in expanding male testosterone indications.
This is one of the most frequently blurred—and clinically consequential—distinctions in women’s hormone therapy.
Progesterone is the bioidentical molecule identical to the hormone produced by the human ovary and placenta. When prescribed, it is typically micronized progesterone. It is used primarily to protect the endometrium when systemic estrogen is given to women who still have a uterus, and it is also studied for sleep, mood, and other effects.
Progestins (also called progestogens in some literature) are synthetic compounds engineered to bind progesterone receptors. They include medroxyprogesterone acetate (the agent used in the Women’s Health Initiative combination arm), norethindrone, levonorgestrel, and others. Their chemical structures, metabolites, and downstream effects differ from natural progesterone.
The practical consequences are significant:
The small increase in breast-cancer risk seen in the WHI combination arm is attributed to the synthetic progestin, not to estrogen itself. The estrogen-only arm of the same trial showed a reduction in breast-cancer incidence.
Studies that used conjugated estrogens with little or no progestin (or low-dose natural progesterone) have not shown the same breast-cancer signal.
Media reports, older guidelines, and even some peer-reviewed papers routinely say “progesterone” when they mean a synthetic progestin. This linguistic conflation perpetuates fear and leads to unnecessary withholding of therapy.
Modern practice increasingly favors micronized progesterone over synthetic progestins for endometrial protection precisely because of these differences in risk profile and side-effect experience.
Bosserman repeatedly stresses that failing to make this distinction is not a minor semantic issue—it is a source of real clinical harm. When patients or clinicians hear “progesterone increases breast cancer risk,” they are usually hearing a statement about synthetic progestins that has been incorrectly generalized.
Premarin versus Bioidentical Hormones
Premarin (conjugated equine estrogens) is a complex mixture of estrogens derived from pregnant mare urine. It contains multiple equine estrogens, some of which are not identical to human estradiol. Oral Premarin was the estrogen used in the Women’s Health Initiative and carries a clearer association with venous thromboembolism risk in the first year (still lower than pregnancy risk, but higher than baseline).
Bioidentical hormones refer to molecules structurally identical to those produced by the human body:
Estradiol (17β-estradiol)
Progesterone (micronized)
Testosterone
These can be delivered orally, transdermally, vaginally, or via other routes. Oral estradiol has long-term randomized data (including DOPS) showing no increased clotting risk comparable to the conjugated-equine signal and favorable cardiovascular outcomes when started near menopause. The clinical difference is not ideological; it is chemical and pharmacokinetic. Guidelines that blanket-state “oral estrogens increase clotting” without distinguishing conjugated equine estrogens from estradiol oversimplify the evidence.
Action Steps You Can Take
Demand specificity. When any clinician or article says “hormones,” ask: which molecule, which dose, which route, for which indication, and based on which data?
Prioritize local therapy first if genitourinary symptoms are present. Low-dose vaginal estradiol has a strong safety profile even after breast cancer and should not be withheld solely because of a history of hormone-receptor-positive disease.
Request an individualized risk discussion if you are a cancer survivor. Stage, receptor status, time since treatment, and competing risks (cardiovascular disease is still the leading cause of death for most women) all matter. “Never” is rarely an evidence-based answer.
Explore testosterone with a knowledgeable clinician if energy, cognition, mood, or sexual function are impaired—especially after ovarian removal or prolonged estrogen suppression. Track how you feel, not just a single lab number.
Address the foundations that move risk more than most hormone regimens: consistent movement, sleep, metabolic health, and weight management. Hormones often make these behaviors more sustainable.
Seek second opinions and share primary literature. Many oncologists and primary-care clinicians are simply unfamiliar with the post-WHI re-analyses, DOPS, Stockholm study contrasts with HABIT, and the testosterone observational data. Bring the papers.
Advocate for better products and coverage. The lack of an FDA-approved female testosterone preparation and restrictive insurance policies for both men and women remain structural barriers.
Women have been taught to accept diminished quality of life as inevitable after menopause or cancer treatment. The clinicians in this conversation reject that premise. Accurate hormone information, individualized decision-making, and attention to the whole person—bio, psycho, and social—are not radical. They are overdue.
